Overview

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of QL0911 to prevention chemotherapy-induced thrombocytopenia. Thrombocytopenia is a low number of platelets in the blood. Sometimes, thrombocytopenia occurs as a side effect of chemotherapy treatments.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.